Reversibility of hepatitis B virus cirrhosis after therapy: Who and why?

Liver International

Volumn 35, Issue s1, 2015, Pages 78-81

  Bedossa, Pierre ^a  

^a BEAUJON HOSPITAL   (France)

Author keywords

Cirrhosis; Fibrosis; Reversion; Virus B

Indexed keywords

ANTIVIRAL AGENTS;

COMPLICATION; DRUG EFFECTS; HEPATITIS B; HEPATITIS B VIRUS; HUMANS; LIVER CIRRHOSIS; PATHOLOGY; TREATMENT OUTCOME;

ANTIVIRAL AGENTS; HEPATITIS B; HEPATITIS B VIRUS; HUMANS; LIVER CIRRHOSIS; TREATMENT OUTCOME;

EID: 84919629272     PISSN: 14783223     EISSN: 14783231     Source Type: Journal    
DOI: 10.1111/liv.12710     Document Type: Review

References (27)

1. Bedossa P, Poynard T. An algorithm for the grading of activity in chronic hepatitis C. The METAVIR Cooperative Study Group. Hepatology 1996; 24: 289-93.
2. Asselah T, Marcellin P, Bedossa P. Improving performance of liver biopsy in fibrosis assessment. J Hepatol 2014; 61: 193-5.
3. Friedman S. Mechanisms of hepatic fibrogenesis. Gastroenterology 2008; 134: 1655-69.
4. Anthony PP, Ishak KG, Nayak NC, Poulsen HE, Scheur PJ, Sobin LH. The morphology of cirrhosis. Recommendations on definition, nomenclature, and classification by a working group sponsored by the World Health Organization. J Clin Pathol 1978; 31: 395-414.
5. Perez-Tamayo R. Cirrhosis of the liver: a reversible disease? Pathol Annu 1979; 14: 183-213.
6. Abdel-Aziz G, Lebeau G, Rescan PY, et al. Reversibility of hepatic fibrosis in experimentally induced cholestasis in rat. Am J Pathol 1990; 137: 1333-42.
7. Wanless IR, Nakashima E, Sherman M. Regression of human cirrhosis. Morphologic features and the genesis of incomplete septal cirrhosis. Arch Pathol Lab Med 2000; 124: 1599-607.
8. Calvaruso V, Craxi A Regression of fibrosis after HBV antiviral therapy. Is cirrhosis reversible? Liver Int 2014; 34: 85-90.
9. Marcellin P, Asselah T. Long-term therapy for chronic hepatitis B: hepatitis B virus DNA suppression leading to cirrhosis reversal. J Gastroenterol Hepatol 2013; 28: 912-23.
10. Dienstag JL, Goldin RD, Heathcote EJ, et al. Histological outcome during long-term lamivudine therapy. Gastroenterology 2003; 124: 105-17.
11. Hadziyannis SJ, Tassopoulos NC, Heathcote EJ, et al. Longterm therapy with adefovir dipivoxil for HBeAg-negative chronic hepatitis B for up to 5 years. Gastroenterology 2006; 131: 1743-51.
12. Schiff ER, Lee SS, Chao YC, et al. Long-term treatment with entecavir induces reversal of advanced fibrosis or cirrhosis in patients with chronic hepatitis B. Clin Gastroenterol Hepatol 2011; 9: 274-6.
13. Chang TT, Liaw YF, Wu SS, et al. Long-term entecavir therapy results in the reversal of fibrosis/cirrhosis and continued histological improvement in patients with chronic hepatitis B. Hepatology 2010; 52: 886-93.
14. Marcellin P, Gane E, Buti M, et al. Regression of cirrhosis during treatment with tenofovir disoproxil fumarate for chronic hepatitis B: a 5-year open-label follow-up study. Lancet 2013; 381: 468-475.
15. Arthur MJ. Collagenases and liver fibrosis. J Hepatol 1995; 22: 43-8.
16. Iredale JP, Benyon RC, Pickering J, et al. Mechanisms of spontaneous resolution of rat liver fibrosis. Hepatic stellate cell apoptosis and reduced hepatic expression of metalloproteinase inhibitors. J Clin Invest 1998; 102: 538-49.
17. Issa R, Zhou X, Constandinou CM, et al. Spontaneous recovery from micronodular cirrhosis: evidence for incomplete resolution associated with matrix cross-linking. Gastroenterology 2004; 126: 1795-808.
18. Rudolph KL, Chang S, Millard M, et al. Inhibition of experimental liver cirrhosis in mice by telomerase gene delivery. Science 2000; 287: 1253-8.
19. Paradis V, Youssef N, Dargere D, et al. Replicative senescence in normal liver, chronic hepatitis C, and hepatocellular carcinomas. Hum Pathol 2001; 32: 327-32.
20. Kim SU, Oh HJ, Wanless IR, Lee S, Han KH, Park YN. The Laennec staging system for histological sub-classification of cirrhosis is useful for stratification of prognosis in patients with liver cirrhosis. J Hepatol 2012; 57: 556-63.
21. Kim SU, Park JY, Kim DY, et al. Non-invasive assessment of changes in liver fibrosis via liver stiffness measurement in patients with chronic hepatitis B: impact of antiviral treatment on fibrosis regression. Hepatol Int 2010; 4: 673-80.
22. Lin SM, Yu ML, Lee CM, et al. Interferon therapy in HBeAg positive chronic hepatitis reduces cirrhosis and hepatocellular carcinoma. J Hepatol 2007; 46: 45-52.
23. Manolakopoulos S, Triantos C, Theodoropoulos J, et al. Antiviral therapy reduces portal pressure in patients with cirrhosis due to HBeAg-negative chronic hepatitis B and significant portal hypertension. J Hepatol 2009; 51: 468-74.
24. Yao FY, Terrault NA, Freise C, et al. Lamivudine treatment is beneficial in patients with severely decompensated cirrhosis and actively replicating hepatitis B infection awaiting liver transplantation: a comparative study using a matched, untreated cohort. Hepatology 2001; 34: 411-6.
25. Maylin S, Martinot-Peignoux M, Moucari R, et al. Eradication of hepatitis C virus in patients successfully treated for chronic hepatitis. Gastroenterology 2008; 135: 821-9.
26. Mallet V, Gilgenkrantz H, Serpaggi J, et al. Brief communication: the relationship of regression of cirrhosis to outcome in chronic hepatitis C. Ann Intern Med 2008; 149: 399-403.
27. Papatheodoridis GV, Dalekos GN, Yurdaydin C, et al. Incidence and predictors of hepatocellular carcinoma in Caucasian chronic hepatitis B patients receiving entecavir or tenofovir. J Hepatol 2014; doi: 10.1016/j.jhep.2014.08.045.